Clinical Trial

Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not). Both of these are important screening elements to Aim 3 of a National Institutes of Health Grant. The purposes of Aim 3 are to determine 1. whether a high dietary sodium level appropriately expands plasma volume in Postural Orthostatic Tachycardia, 2. whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in Postural Tachycardia Syndrome and 3. whether patients with Postural Tachycardia Syndrome have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2013-01-31; most recent amendment 2026-01-12.
Status change: Recruiting → Active, Not Recruiting 2016-07-18
Trial Details
NCT Number NCT01783288
Lead Sponsor Vanderbilt University
Collaborators: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Conditions Postural Tachycardia Syndrome
Enrollment 110 participants
Start Date 2013-02
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-13